Market Overview

Myriad's Presents Positive Clinical Data on HRD Test at SABCS 2013

Myriad Genetics (Nasdaq: MYGN) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD (homologous recombination deficiency) test was significantly associated with cisplatin response in patients with triple negative breast cancer.

In this research study, Myriad's HRD test provided optimal prediction of platinum response in patients with triple negative disease (p=0.0003). The HRD score predicted all of the patients that experienced a complete response after pre-surgical treatment with platinum with a sensitivity of 100 percent. Furthermore, these results showed that the HRD score not only predicted drug response in triple negative patients but the HRD score also was generalizable across all breast cancer subtypes.

See full press release

Posted-In: News Guidance FDA Management Global

 

Related Articles (MYGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters